Avalo Therapeutics (AVTX) Amortization of Deferred Charges (2014 - 2018)

Avalo Therapeutics has reported Amortization of Deferred Charges for 5 years, with the latest figure at -$24342.0 in Q4 2018.

• For the quarter ending Q4 2018, Amortization of Deferred Charges fell 2434100.0% year-over-year to -$24342.0; the trailing twelve-month figure through Sep 2019 stood at -$24342.0 (down 107.44% YoY), and the FY2018 full-year result was $302882.0, up 1387.34% from the prior year.
• Amortization of Deferred Charges for Q4 2018 stood at -$24342.0, roughly flat from -$24342.0 in the prior quarter.
• The five-year high for Amortization of Deferred Charges was $246115.0 in Q2 2018, with the low at -$24342.0 in Q3 2018.
• Historically, Amortization of Deferred Charges has averaged $48444.5 across 5 years, with a median of $36946.0 in 2016.
• The largest YoY upside for Amortization of Deferred Charges was 2990.73% in 2018 against a maximum downside of 2434100.0% in 2018.
• Avalo Therapeutics' Amortization of Deferred Charges stood at $44292.0 in 2014, then soared by 100.91% to $88989.0 in 2015, then slumped by 68.34% to $28174.0 in 2016, then slumped by 100.0% to -$1.0 in 2017, then tumbled by 2434100.0% to -$24342.0 in 2018.
• The last three Amortization of Deferred Charges figures came in at -$24342.0 (Q4 2018), -$24342.0 (Q3 2018), and $246115.0 (Q2 2018), per Business Quant data.